Glofitamab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 173 publications
Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.
Journal: Oncology (Williston Park, N.Y.)
Published: June 22, 2026
Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: June 10, 2026
Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.
Journal: Expert opinion on drug discovery
Published: June 08, 2026
Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspective.
Journal: Journal of comparative effectiveness research
Published: April 20, 2026
"Immunologic Dream Team": BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.
Journal: Blood advances
Published: March 30, 2026
Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis.
Journal: Translational cancer research
Published: March 23, 2026
Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.
Journal: Journal of hematology & oncology
Published: March 09, 2026
Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Haematologica
Published: March 04, 2026
Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study.
Journal: Frontiers in pharmacology
Published: February 28, 2026
The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.
Journal: Expert review of anticancer therapy
Published: February 24, 2026
TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.
Journal: Annals of hematology
Published: February 24, 2026
Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
Journal: The oncologist
Published: February 18, 2026
Last Updated: 06/30/2026